202
M. Irfan et al.
42. Jia W, Ren C, Wang L, Zhu B, Jia W, Gao M, Zeng F, Zeng L, Xia X, Zhang X (2016) CD109
is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by
cell-SELEX. Oncotarget 7(34):55328
43. Rong Y, Chen H, Zhou X-F, Yin C-Q, Wang B-C, Peng C-W, Liu S-P, Wang F-B (2016)
Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver
cancers. Oncotarget 7(7):8282
44. Xiao Z, Luo G, Liu C, Wu C, Liu L, Liu Z, Ni Q, Long J, Yu X (2014) Molecular mechanism
underlying lymphatic metastasis in pancreatic cancer. Biomed Res Int 2014:925845
45. Kim YJ, Lee HS, Jung DE, Kim JM, Song SY (2017) The DNA aptamer binds stemnessenriched cancer cells in pancreatic cancer. J Mol Recognit 30(4):e2591
46. Benedetto G, Hamp TJ, Wesselman PJ, Richardson C (2015) Identification of epithelial
ovarian tumor-specific aptamers. Nucl Acid Ther 25(3):162–172
47. Jiang L, Wang H, Chen S (2020) Aptamer (AS1411)-conjugated liposome for enhanced
therapeutic efficacy of miRNA-29b in Ovarian Cancer. J Nanosci Nanotechnol 20(4):2025–
2031
48. Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L (2016) EpCAM aptamer-functionalized
mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur J
Pharm Sci 83:28–35
49. Wan J, Ye L, Yang X, Guo Q, Wang K, Huang Z, Tan Y, Yuan B, Xie Q (2015) CellSELEX based selection and optimization of DNA aptamers for specific recognition of human
cholangiocarcinoma QBC-939 cells. Analyst 140(17):5992–5997
50. Wang L, Li P, Xiao X, Li J, Li J, Yang H-H, Tan W (2018) Generating lung-metastatic
osteosarcoma targeting aptamers for in vivo and clinical tissue imaging. Talanta 188:66–73
51. Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, Meng L, Smith JE, Tan W (2008)
Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem Chem
Enabling Drug Discov 3(6):991–1001
52. Zhou W, Zhao L, Yuan H, Xu L, Tan W, Song Y, Fang X (2019) A new small cell lung cancer
biomarker identified by Cell-SELEX generated aptamers. Exp Cell Res 382(2):111478
53. Afrasiabi S, Pourhajibagher M, Raoofian R, Tabarzad M, Bahador A (2020) Therapeutic
applications of nucleic acid aptamers in microbial infections. J Biomed Sci 27(1):6
54. Percival S (2017) Importance of biofilm formation in surgical infection. Br J Surg 104(2):e85–
e94
55. Hall CW, Mah T-F (2017) Molecular mechanisms of biofilm-based antibiotic resistance and
tolerance in pathogenic bacteria. FEMS Microbiol Rev 41(3):276–301
56. Ning Y, Cheng L, Ling M, Feng X, Chen L, Wu M, Deng L (2015) Efficient suppression of
biofilm formation by a nucleic acid aptamer. Pathog Dis 73 (6):ftv034
57. Henriques-Normark B, Tuomanen EI (2013) The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harbor Perspectives in Medicine 3(7):a010215
58. Bayrac AT, Donmez SI (2018) Selection of DNA aptamers to Streptococcus pneumonia and
fabrication of graphene oxide based fluorescent assay. Anal Biochem 556:91–98
59. Wang S, Mao B, Wu M, Liang J, Deng L (2018) Influence of aptamer-targeted antibiofilm
agents for treatment of Pseudomonas aeruginosa biofilms. Antonie Van Leeuwenhoek
111(2):199–208
60. Liang X, Ji Y (2007) Involvement of α5β1-integrin and TNF-α in Staphylococcus aureus
α-toxin-induced death of epithelial cells. Cell Microbiol 9(7):1809–1821
61. Vivekananda J, Salgado C, Millenbaugh NJ (2014) DNA aptamers as a novel approach to
neutralize Staphylococcus aureus α-toxin. Biochem Biophys Res Commun 444(3):433–438
62. Ortega E, Abriouel H, Lucas R, Gálvez A (2010) Multiple roles of Staphylococcus aureus
enterotoxins: pathogenicity, superantigenic activity, and correlation to antibiotic resistance.
Toxins 2(8):2117–2131
63. Wang K, Gan L, Jiang L, Zhang X, Yang X, Chen M, Lan X (2015) Neutralization of
staphylococcal enterotoxin B by an aptamer antagonist. Antimicrob Agents Chemother
59(4):2072–2077
M. Irfan et al.
42. Jia W, Ren C, Wang L, Zhu B, Jia W, Gao M, Zeng F, Zeng L, Xia X, Zhang X (2016) CD109
is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by
cell-SELEX. Oncotarget 7(34):55328
43. Rong Y, Chen H, Zhou X-F, Yin C-Q, Wang B-C, Peng C-W, Liu S-P, Wang F-B (2016)
Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver
cancers. Oncotarget 7(7):8282
44. Xiao Z, Luo G, Liu C, Wu C, Liu L, Liu Z, Ni Q, Long J, Yu X (2014) Molecular mechanism
underlying lymphatic metastasis in pancreatic cancer. Biomed Res Int 2014:925845
45. Kim YJ, Lee HS, Jung DE, Kim JM, Song SY (2017) The DNA aptamer binds stemnessenriched cancer cells in pancreatic cancer. J Mol Recognit 30(4):e2591
46. Benedetto G, Hamp TJ, Wesselman PJ, Richardson C (2015) Identification of epithelial
ovarian tumor-specific aptamers. Nucl Acid Ther 25(3):162–172
47. Jiang L, Wang H, Chen S (2020) Aptamer (AS1411)-conjugated liposome for enhanced
therapeutic efficacy of miRNA-29b in Ovarian Cancer. J Nanosci Nanotechnol 20(4):2025–
2031
48. Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L (2016) EpCAM aptamer-functionalized
mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur J
Pharm Sci 83:28–35
49. Wan J, Ye L, Yang X, Guo Q, Wang K, Huang Z, Tan Y, Yuan B, Xie Q (2015) CellSELEX based selection and optimization of DNA aptamers for specific recognition of human
cholangiocarcinoma QBC-939 cells. Analyst 140(17):5992–5997
50. Wang L, Li P, Xiao X, Li J, Li J, Yang H-H, Tan W (2018) Generating lung-metastatic
osteosarcoma targeting aptamers for in vivo and clinical tissue imaging. Talanta 188:66–73
51. Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, Meng L, Smith JE, Tan W (2008)
Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem Chem
Enabling Drug Discov 3(6):991–1001
52. Zhou W, Zhao L, Yuan H, Xu L, Tan W, Song Y, Fang X (2019) A new small cell lung cancer
biomarker identified by Cell-SELEX generated aptamers. Exp Cell Res 382(2):111478
53. Afrasiabi S, Pourhajibagher M, Raoofian R, Tabarzad M, Bahador A (2020) Therapeutic
applications of nucleic acid aptamers in microbial infections. J Biomed Sci 27(1):6
54. Percival S (2017) Importance of biofilm formation in surgical infection. Br J Surg 104(2):e85–
e94
55. Hall CW, Mah T-F (2017) Molecular mechanisms of biofilm-based antibiotic resistance and
tolerance in pathogenic bacteria. FEMS Microbiol Rev 41(3):276–301
56. Ning Y, Cheng L, Ling M, Feng X, Chen L, Wu M, Deng L (2015) Efficient suppression of
biofilm formation by a nucleic acid aptamer. Pathog Dis 73 (6):ftv034
57. Henriques-Normark B, Tuomanen EI (2013) The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harbor Perspectives in Medicine 3(7):a010215
58. Bayrac AT, Donmez SI (2018) Selection of DNA aptamers to Streptococcus pneumonia and
fabrication of graphene oxide based fluorescent assay. Anal Biochem 556:91–98
59. Wang S, Mao B, Wu M, Liang J, Deng L (2018) Influence of aptamer-targeted antibiofilm
agents for treatment of Pseudomonas aeruginosa biofilms. Antonie Van Leeuwenhoek
111(2):199–208
60. Liang X, Ji Y (2007) Involvement of α5β1-integrin and TNF-α in Staphylococcus aureus
α-toxin-induced death of epithelial cells. Cell Microbiol 9(7):1809–1821
61. Vivekananda J, Salgado C, Millenbaugh NJ (2014) DNA aptamers as a novel approach to
neutralize Staphylococcus aureus α-toxin. Biochem Biophys Res Commun 444(3):433–438
62. Ortega E, Abriouel H, Lucas R, Gálvez A (2010) Multiple roles of Staphylococcus aureus
enterotoxins: pathogenicity, superantigenic activity, and correlation to antibiotic resistance.
Toxins 2(8):2117–2131
63. Wang K, Gan L, Jiang L, Zhang X, Yang X, Chen M, Lan X (2015) Neutralization of
staphylococcal enterotoxin B by an aptamer antagonist. Antimicrob Agents Chemother
59(4):2072–2077